Evidence map›Paper›PMID 26879972›Full record

Trial reportPediatric rheumatology online journal2016

Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry.

Lauren A Henderson, David Zurakowski, Sheila T Angeles-Han, Andrew Lasky, C Egla Rabinovich, Mindy S Lo, Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Investigators

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatric rheumatology online journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Guideline
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Pediatric uveitis: Role of the pediatrician.Frontiers in pediatrics · 2022
    Review
  12. Uveitis in Children and Adolescents.Rheumatic diseases clinics of North America · 2021
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.Current treatment options in rheumatology · 2017
    Article
  20. Uveitis in children.Current opinion in rheumatology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lauren A HendersonDivision of Immunology, Boston Children's Hospital, Boston, MA and Department of Pediatrics, Harvard Medical School, 1 Blackfan Circle, Karp Building, 10th Floor, Boston, MA, 02115, USA. Lauren.Henderson@childrens.harvard.edu.
David ZurakowskiDepartments of Anesthesia and Surgery, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA. david.zurakowski@childrens.harvard.edu.
Sheila T Angeles-HanDepartment of Pediatrics and Ophthalmology, Emory University School of Medicine, Atlanta, GA, USA. sangele@emory.edu.
Andrew LaskyDepartment of Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, USA. Alasky@lhs.org.
C Egla RabinovichDivision of Rheumatology, Department of Pediatrics, Duke Children's, Durham, NC, USA. egla.rabinovich@duke.edu.
Mindy S LoDivision of Immunology, Boston Children's Hospital, Boston, MA and Department of Pediatrics, Harvard Medical School, 1 Blackfan Circle, Karp Building, 10th Floor, Boston, MA, 02115, USA. Mindy.Lo@childrens.harvard.edu.
Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Investigators
Boston Children's Hospital · USEmory University · USRandall Children's Hospital at Legacy Emanuel · US

Funding

MOLECULAR BASIS OF ALLERGIC AND IMMUNOLOGIC DISEASET32AI007512 · NIAID · CHILDREN'S HOSPITAL BOSTON · PI Janet Chou, Peter A Nigrovic · 1996 to 2026
$13.1M
CARRA: Accelerating Toward an Evidence Based Culture in Pediatric RheumatologyRC2AR058934 · NIAMS · DUKE UNIVERSITY · PI ILOWITE, NORMAN T, SANDBORG, CHRISTY IRENE · 2009 to 2010
$6.8M
Outcomes of children with juvenile idiopathic arthritis-associated uveitisK23EY021760 · NEI · EMORY UNIVERSITY · PI ANGELES-HAN, SHEILA THERESE · 2011 to 2015
$980k
NEI NIH HHS K23EY021760NIAID NIH HHS T32AI007512NIAMS NIH HHS L40 AR065238NIAMS NIH HHS RC2AR058934
6 · The paper itself

Abstract

backgroundThere is not yet a commonly accepted, standardized approach in the treatment of juvenile idiopathic uveitis when initial steroid therapy is insufficient. We sought to assess current practice patterns within a large cohort of children with juvenile uveitis.

methodsThis is a cross-sectional cohort study of patients with uveitis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRAnet) registry. Clinical information including, demographic information, presenting features, disease complications, and medications were collected. Chi-square and Fisher's exact tests were used to assess for associations between medications and clinical characteristics.

resultsNinety-two children with idiopathic and 656 with juvenile idiopathic arthritis (JIA)-associated uveitis were identified. Indication (arthritis or uveitis) for medication use was not available for JIA patients; therefore, detailed analysis was limited to children with idiopathic uveitis. In this group, 94 % had received systemic steroids. Methotrexate (MTX) was used in 76 % of patients, with oral and subcutaneous forms given at similar rates. In multivariable analysis, non-Caucasians were more likely to be treated initially with subcutaneous MTX (P = 0.003). Of the 53 % of patients treated with a biologic DMARD, all received a tumor necrosis factor (TNF) inhibitor. TNF inhibitor use was associated with a higher frequency of cataracts (52 % vs 21 %; P = 0.001) and antinuclear antibody positivity (49 % vs 29 %; P = 0.04), although overall complication rates were not higher in these patients.

conclusionAmong idiopathic uveitis patients enrolled in the CARRAnet registry, MTX was the most commonly used DMARD, with subcutaneous and oral forms equally favored. Patients who received a TNF inhibitor were more likely to be ANA positive and have cataracts.

Indexed as

Biomedical ResearchRegistriesAdalimumabAntirheumatic AgentsArthritis, JuvenileCross-Sectional StudiesDrug Therapy, CombinationFemaleFollow-Up StudiesHumansInfliximabMaleMethotrexateRetrospective StudiesRheumatologyUveitisAdalimumabAntirheumatic AgentsInfliximabMethotrexate

Identifiers

PMID26879972
PMCPMC4755024
OpenAlexW2278759026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.